Rallybio Co. (NASDAQ:RLYB) Expected to Post Earnings of -$0.48 Per Share

Wall Street analysts expect Rallybio Co. (NASDAQ:RLYBGet Rating) to post earnings per share (EPS) of ($0.48) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Rallybio’s earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.46). The company is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Rallybio will report full year earnings of ($2.23) per share for the current financial year, with EPS estimates ranging from ($2.30) to ($2.15). For the next fiscal year, analysts forecast that the company will post earnings of ($2.54) per share, with EPS estimates ranging from ($2.57) to ($2.51). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Rallybio.

Rallybio (NASDAQ:RLYBGet Rating) last issued its earnings results on Tuesday, March 15th. The company reported ($0.42) EPS for the quarter.

RLYB has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Rallybio from a “hold” rating to a “sell” rating in a research report on Saturday, March 19th. JMP Securities reduced their price target on shares of Rallybio from $32.00 to $29.00 and set a “market outperform” rating for the company in a research report on Wednesday, March 16th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $24.75.

Shares of RLYB stock traded up $0.99 on Thursday, reaching $11.07. 2,872 shares of the stock were exchanged, compared to its average volume of 108,279. The business’s 50 day moving average price is $8.95 and its 200 day moving average price is $11.29. Rallybio has a twelve month low of $6.74 and a twelve month high of $25.78.

Several large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Rallybio by 11.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 16,076 shares of the company’s stock valued at $154,000 after buying an additional 1,628 shares during the last quarter. Citigroup Inc. raised its holdings in Rallybio by 241.7% during the fourth quarter. Citigroup Inc. now owns 2,805 shares of the company’s stock worth $27,000 after purchasing an additional 1,984 shares in the last quarter. Morgan Stanley purchased a new position in Rallybio during the third quarter worth about $38,000. Allspring Global Investments Holdings LLC purchased a new position in Rallybio during the fourth quarter worth about $27,000. Finally, Bank of America Corp DE raised its holdings in Rallybio by 527.2% during the fourth quarter. Bank of America Corp DE now owns 3,939 shares of the company’s stock worth $38,000 after purchasing an additional 3,311 shares in the last quarter. 92.87% of the stock is owned by institutional investors and hedge funds.

Rallybio Company Profile (Get Rating)

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Featured Articles

Get a free copy of the Zacks research report on Rallybio (RLYB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.